Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Synthetic Biologics Inc (NY: SYN )

N/A UNCHANGED
Last Price Updated: 8:00 PM EDT, Oct 12, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 1.040 (20)
Ask (Size) 1.140 (1)
Prev. Close 1.020
Today's Range N/A - N/A
52wk Range N/A - N/A
Shares Outstanding 25,131,230
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why NanoViricides Jumped Over 48%; Here Are 106 Biggest Movers From Yesterday
Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) surged 109.2% to settle at $50.43 on Thursday after the company, and Amgen, announced an agreement under which Amgen will acquire the company for $52 per share... 
Via Benzinga
Earnings Scheduled For May 16, 2022
Companies Reporting Before The Bell • AcelRx Pharmaceuticals (NASDAQ:ACRX) is estimated to report quarterly loss at $0.06 per share on revenue of $550.00 thousand. 
Via Benzinga

Performance

More News

Read More
Synthetic Biologics Posts Encouraging Safety Data on SYN-020 In Healthy Volunteers
Via Benzinga
Earnings Scheduled For August 11, 2022
Via Benzinga
Why Is Yellow Trading Higher By 33%: Here Are 48 Stocks Moving Premarket
Via Benzinga
Daily Biotech Pulse: KKR Invests In Medicine Start-Up, Revelation Bio Aces Allergic Rhinitis Study, Tonix Pharma Ends COVID-19 Antiviral Pact
Via Benzinga
Why ChemoCentryx Is Trading Higher By 110%, Here Are 95 Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Boeing And 24 Stocks Moving Premarket
Via Benzinga
Why Bank Stocks Traded Sharply Higher; Here's 65 Biggest Movers From Friday
Via Benzinga
Crude Oil Rises By More Than 2%; Codexis Shares Plummet
Via Benzinga
Dow Jumps More Than 600 Points; Citigroup Tops Q2 Expectations
Via Benzinga
The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More
Via Benzinga
Recap: Synthetic Biologics Q1 Earnings
Via Benzinga
Citigroup, Bank of America And 48 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Synthetic Biologics' VCN-01 Shows Favorable Safety Profile, Clinical Activity In Early-Stage Cancer Study
Via Benzinga
53 Biggest Movers From Yesterday
Via Benzinga
The Week Ahead In Biotech (March 20-26): Focus On Zogenix FDA Decision, Dermatology Conference Presentations & Earnings
Via Benzinga
64 Biggest Movers From Yesterday
Via Benzinga
Synthetic Biologics: Q4 Earnings Insights
Via Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study
Via Benzinga
Earnings Scheduled For March 16, 2022
Via Benzinga
Earnings Outlook For Synthetic Biologics
Via Benzinga
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.